Tenascin C (TNC) Mouse Monoclonal Antibody [Clone ID: EB2]

Specifications

Product Data
Clone Name	EB2
Applications	ELISA, IHC, WB
Recommend Dilution	Western blotting (highly sensitive). Immunohistochemistry on Frozen Sections. Other Immunoassays for cellular and tumor biology. Quantitation of Tn-C in body fluids together with clone DB7 Cat.-No AM32094PU-N (ref. 8).
Reactivity	Guinea Pig, Human, Rabbit
Host	Mouse
Clonality	Monoclonal
Immunogen	Purified Tenascin-C from human fetal fibroblasts. Hybridoma produced by fusion between myeloma cells and Balb/c spleen cells.
Specificity	The antibody clone EB2 reacts with the 4th and 5th fibronectin-like repeats of Human Tenascin-C polypeptides of Mr 250000 and 180000.
Formulation	PBS State: Ig Fraction State: Liquid Ig fraction Stabilizer: 1.0% BSA Preservative: 0.09% Sodium Azide
Concentration	lot specific
Conjugation	Unconjugated
Storage Condition	Store the antibody undiluted at 2-8°C.
Gene Name	tenascin C
Database Link	Entrez Gene 3371 Human UniProt ID P24821
Background	Tenascins were first characterized in the early 1980’s. Since then hundreds of publications on tenascin in normal tissues, pathologically reactive tissues and carcinomas have been published. However, only recently more elective studies have been done. In these studies retrospective material from pathology files has been studied as well as larger fresh material collected during several years from patients. These studies have now attempted to reveal more specific points in carcinogenesis and pathological tissue reactions. It has been demonstrated that tenascin immunoreactivity in breast carcinoma cells could be indicative of metastasis and survival. Recent studies using retrospective material showed that the expression of tenascin in invasion border of early breast cancer significantly correlates with higher risk of distant metastasis. These studies have been continued now and the preliminary results clearly suggest that expression of tenascin in invasion border of early breast cancer is significantly associated with proliferative activity and higher risk of local recurrence. This result implicates a wide application for tenascin antibodies in the breast pathology. The point is that tenascin expression may suggest situations in which even small breast carcinomas may need more intensive complementary therapy (chemotherapy etc.). Recent studies have also shown that tenascin is significantly increased in airway basement membrane of asthmatics and rapidly decreases by inhaled steroid. This result suggests that tenascin expression may be used to monitor the disease status and outcome of treatment in different types of asthma.
Synonyms	Tenascin-C, TN-C, Hexabrachion, Cytotactin, Neuronectin, GMEM
Reference Data

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.